Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease of unknown etiology. Both genetic and environmental factors have been shown to be relevant, contributory factors to the expression and complications of this disease. [1, 2] The prevalence of RA is about 1% of the total population, and genetic factors have been estimated to account for 60% of the disease risk. [3] Glutathione S-transferase (GST) genes, known as a superfamily of phase II metabolic enzymes, catalyze the detoxification of xenobiotics via glutathione conjugation. They are also believed to play an important role in detoxifying products generated by the activity of reactive oxygen species (ROS). The glutathione S-transferase Mu 1 (GSTM1), glutathione S-transferase P 1 (GSTP1), and glutathione S-transferase theta 1 (GSTT1) genes are mapped on chromosome 1 (1p13.3), chromosome 11 (11q13), and chromosome 22 (22q11.2), respectively. [4] There is evidence that some allelic variants are associated with differences in detoxification efficiency. In addition, these three genes have been shown to have functional polymorphisms that are frequently present in the general population. [5] Individuals with homozygous deletions at the M1 and T1 loci of GST (GSTM1 null and GSTT1 null, respectively) have no functional enzymatic activity. Deletions in the GSTM1 and GSTT1 genes occur with varying frequencies in different populations. It has been reported that a one point mutation in the coding region of the GSTP1 gene results in the substitution of isoleucine (Ile) for valine (Val) at codon 105, which modifies the enzyme activity. [6, 7] Glutathione S-transferases have peroxidase activity concerning cytotoxic metabolites that are produced in inflammatory reactions, and this is the main feature of RA. In addition, it has been proposed that defense mechanisms against ROS are impaired in RA.
Though there are several studies regarding the association between GSTs polymorphisms and the risk of RA, the findings are controversial. Therefore, the aim of the present study was to evaluate the impact of GSTs polymorphisms on the susceptibility to RA in a sample of Iranian population.
PATIENTS AND METHODS
This case-control study was performed from October 2010 to March 2012 in Clinic of Rheumatology, Ali-Ebneh Abitaleb hospital Zahedan, Iran. We investigated the possible association between the GSTM1, GSTT1, GSTP1 polymorphisms of GSTs genes and RA susceptibility in 100 patients (88 females and 12 males; mean age 44.1±13.2 years; range 17 to 75 years) who fulfilled the American College of Rheumatology (ACR) criteria for RA. [8] All the subjects were patients of the Rheumatology Clinic at Zahedan University of Medical Sciences.
[2,9,10] The control group consisted of 100 healthy individuals (68 females and 32 males; mean age 45.7±9.6 years; range 23 to 70 years) who were unrelated to the RA patients. The ethics committee of the university approved the project, and informed consent was obtained from all patients and healthy individuals. Blood samples from the patients and healthy controls were collected in ethylenedinitrilotetraacetic acid disodium salt (EDTA-Na) tubes. Genomic DNA was then extracted from the peripheral blood samples that had been collected in the tubes containing EDTA in a manner that has been previously described. [10] The GSTM1 and GSTT1 gene polymorphisms Examinations of the GSTM1 and GSTT1 gene polymorphisms were performed using multiplex polymerase chain reaction (PCR), with the TLR2 gene as an internal control, as described by Hashemi et al. [11] The primers used were 5`-GCTGCCCTACTTGATTGATG-3` (sense) and 5`-CCCCAAATCCAAACTCTGTC-3`(anti-sense) for the GSTM1 gene, resulting in a 325-bp fragment; 5`-TTCTGCTTTATGGTGGGGTC-3` (sense) and 5`-GTGATGTTCCCTGTTTTCCT-3` (anti-sense) for the GSTT1 gene, resulting in a 542-bp fragment, and 5`-GATGCATTTGTTTCTTACAGTGAGCG-3` (sense) and 5`-GTGATGTTCCCTGTTTTCCT-3`(anti-sense) for the TLR2 gene, resulting in a 259-bp fragment. The GSTM1 null and GSTT1 null variant forms were defined by the absence of the 325-and 542-bp fragments, respectively.
The GSTP1 polymorphism
The GSTP1 polymorphism was determined by a tetra-primer amplification refractory mutation system PCR (T-ARMS-PCR) as described in an earlier study. [11] Two external primers (forward outer: 5`-CAGGTGT CAGGTGAGCTCTGAGCACC-3` and reverse outer: 5`-ATAAGGGTGCAGGTTGTGTCTTGTCCCA-3`) and two internal primers [forward inner (A allele or Ile allele): 5`-CGTGGAGGACCTCCGCTGCAAATC CA-3` and reverse inner (G allele or Val allele): 5`-GCT CACATAGTTGGTGTAGATGAGGGATAC-3`] were used for detection of the GSTP1 polymorphism. The product sizes were 233-bp for the A allele, 290-bp for the G allele, and 467-bp for the outer primers (control band).
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, Illinois, USA) version 18.0 software program for Windows. The associations between the genotype of the GSTs gene and RA were assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CI) by logistic regression analyses.
RESULTS
The frequency distribution of the GSTM1, GSTT1, and GSTP1 genotypes was compared between 100 RA patients and 100 normal subjects ( Table 1 ). The null genotype of GSTM1 was more prevalent in the patients (78.0%) than in the controls (59.0%), which resulted in a significant association between the incidence of RA and the GSTM1 null genotype (OR=2.86; 95% CI=1.54-5.66; p=0.002). However, no significant difference was observed among the groups regarding the null genotype of GSTT1 (19% versus 11%). The GSTT1 null did not increase the risk of RA (OR=1.85; 95% CI=0.78-4.38; p=0.165). In addition, the results showed that the genotypic and allelic frequencies of GSTP1 did not differ significantly between the RA patients and the control subjects (chi-square=1.69; p=0.429 and chi-square =0.57; p=0.450, respectively).
DISCUSSION
In the present study, we evaluated the association of the GSTM1, GSTT1, and GSTP1 genotypes and the susceptibility to RA in a sample of Iranian population. The findings imply that the GSTM1 null genotype was significantly associated with the risk of RA, though no association was seen between the GSTT1 null genotype and GSTP1 Ile105Val genotypes when examining vulnerability to RA.
In agreement with our findings, Yun et al. [12] reported that the null polymorphism of GSTM1, but not the GSTT1 or GSTP1 genotypes, is associated with an increased risk for RA, but Keenan et al. [13] found no significant differences in the distributions of the GSTP1, GSTT1 and GSTM1 genotypes between RA and healthy subjects. In contrast, Bohanec et al. [14] provided evidence that patients with the GSTT1 null genotype had a higher risk for developing high activity RA than patients with GSTT1 genes present and that the GSTM1 and GSTP1 polymorphisms were not associated with the disease activity.
Glutathione S-transferases, the multifunctional enzymes, promote the detoxification of a wide range of xenobiotics, such as environmental carcinogens, steroids, and ROS. The most common substrates for GSTs are ROS compounds, which are products of oxidative stress (OS). [15] It is well known that individuals with the GSTM1 null or GSTT1 null genotypes display an absence of enzymatic activity and are thought to be at an elevated risk for the cytotoxic effects of a wide spectrum of carcinogens and xenobiotics. [16, 17] In addition, it has been demonstrated that the GSTP1 Ile105Val polymorphism is associated with altered catalytic function and that GSTP1 malfunction makes cells vulnerable to oxidative DNA damage. [18, 19] Given that the GSTM1 and GSTT1 null genotypes along with the GSTP1Ile105Val polymorphism display decreased GST detoxification, they are thought to be potential risk factors that influence susceptibility to RA and impact the outcome of this disease. [12] It has been reported that the risk of developing severe RA disease is increased in female patients who smoke that also have the GSTM1 null polymorphism compared with nonsmoking RA patients with the same genotype. [20] Increased severity in RA has been shown to be associated with a null polymorphism of GSTM1. [21] Furthermore, it has been demonstrated that in both Caucasian and South Asian populations, the GSTT1 null genotype, but not the GSTM1, is associated with RA. [1] Overall, although some small studies have examined the relationship between the polymorphisms of GSTs and the risk of RA, the association still remains unclear, and the debate continues. The reason for the controversial results of these studies could be associated with the differences in the populations studied and their exposures to agents related to RA development. Our findings suggest that the GSTM1 null genotype is a risk factor for susceptibility to RA in a sample of Iranian population. However, this needs to be confirmed by other large studies involving RA.
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